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BACKGROUND: There is no standard of care beyond surgery and radio-
therapy for patients with progressive meningioma. Somatostatin receptors
have been proposed as therapeutic targets. However, systemic administration
of somatostatin analogs has shown only limited efficacy. Somatostatin
receptor-targeted radionuclide therapy represents a novel treatment option
for progressive meningioma. METHODS: In a retrospective analysis, we as-
sessed safety and efficacy of somatostatin receptor-targeted radionuclide
therapy (90Y-DOTATOC (n ¼ 3) or 177Lu-DOTATATE (n ¼ 16) or both
(n ¼ 1)) in 20 patients with progressive, treatment-refractory meningiomas
(histological grading: 5 WHO grade I, 7 WHO grade II, 8 WHO grade III
meningiomas). Changes in the growth rate before and after therapy were as-
sessed by volumetric analysis where applicable. RESULTS: Somatostatin re-
ceptor radionuclide treatment was well tolerated. A median of 3 treatment
cycles were given (median administered dose per cycle 7400 MBq).
Response to treatment was moderate with disease stabilization in 10 of 20 pa-
tients for a median time of 17 months. Median progression-free survival (PFS)
for all patients was 5.4 months, 32.2 months for grade I, 7.6months for grade II
and 2.1 months for grade III meningiomas. PFS correlated inversely with tumor
grade. Median overall survival from start of intervention was not reached at a
medium follow-up time of 20 months. Volumetric measurement showed a re-
duction of more than 25% of growth rate after therapy in 4 of 8 patients ana-
lyzed. Correlation between intensity of somatostatin receptor expression of
singlemeningioma lesions via 68Ga-DOTATOC/-TATE-PET/CTorvia immu-
nohistochemistry and outcome was investigated. CONCLUSION:
Somatostatin receptor-targeted radionuclide treatment is a safe therapy
option inpatients withprogressive meningioma and is effective ina subset ofpa-
tients with WHO grade I and grade II meningioma requiring systemic therapy,
but might have limited efficacy in patients with WHO grade III meningioma.
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